Browse the evidence

GLP-1 receptor agonists are associated with greater reductions in body weight compared to lifestyle interventions and previous medications.

GLP-1 RAs may be a more effective option for weight loss compared to traditional lifestyle changes.

Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.

Practitioners may consider incretin-based therapies as effective treatment options for improving health outcomes in patients with obesity-related HFpEF.

Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.

Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help manage type 2 diabetes mellitus (T2DM) by controlling blood sugar and promoting weight loss.

GLP-1RAs can be considered as a treatment option for patients with T2DM who need to manage blood sugar and weight.

GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.

Practitioners can consider GLP-1RAs as effective options for managing obesity and glycemic control in patients.

GLP-1 medicines reduce food intake, body weight, insulin resistance and inflammation.

GLP-1 medicines can be considered for managing weight and metabolic health in patients with type 2 diabetes and obesity.

Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, are first-line treatment options for type 2 diabetes and obesity.

Healthcare professionals should consider these agents as primary treatment options for managing type 2 diabetes and obesity.

Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.

Semaglutide is the most effective GLP-1 receptor agonist for improving glycemic control and promoting weight loss in T2DM patients.

Emerging oral therapies could complement or serve as alternatives to approved injectable treatments for long-term weight management.

Practitioners should consider these oral therapies as viable options alongside injectables.

Preconception weight optimization in women with obesity is important to reduce maternal and fetal risks.

Practitioners should prioritize weight management in women with obesity planning for pregnancy.

Semaglutide had substantial effects on multiple secondary alcohol-related and somatic outcomes.

Semaglutide may improve various aspects of health related to alcohol use disorder in addition to reducing drinking.

Semaglutide resulted in a similar reduction in body weight across frailty subgroups.

Semaglutide can be used effectively for weight management in patients with obesity-related HFpEF, regardless of frailty status.

GLP-1 receptor agonists or co-agonists have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.

Practitioners may consider GLP-1 receptor agonists as effective options for weight management and improving cardiometabolic health.

Combination strategies using endoscopic bariatric therapies (EBTs) and anti-obesity medications (AOMs) result in greater total-body weight loss than either modality alone.

Combining EBTs with AOMs may enhance weight loss outcomes for patients.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.

Carbohydrate-restricted diets (CRDs) significantly improved glycemic control, including glucose (SMD = -2.94 mg/dL), insulin (SMD = -8.19 pmol/L), and HOMA-IR (-0.54).

Practitioners may consider CRDs as an effective strategy for improving glycemic control in adults.

48.2% of patients who were ineligible for transplant due to elevated body mass index achieved waitlist activation after successful weight loss.

Successful weight loss with semaglutide can enhance transplant eligibility for patients.

Semaglutide initiated 6 months post LSG results in significantly greater absolute weight loss of 14.03 ± 5.26 kg compared to 5.63 ± 6.25 kg in controls from 6 to 12 months post LSG (p < 0.0001).

Practitioners may consider semaglutide as an effective adjunct therapy for weight management in patients post-sleeve gastrectomy.

Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).

Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.

At 12 months, total weight loss was higher in the treatment group (35.77% ± 8.35%) compared to controls (28.37% ± 7.41%; p < 0.0001).

The findings support the use of semaglutide for improved long-term weight management post-surgery.

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).

Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.